KaloBios Pharmaceuticals Raises $12M

South San Francisco-based KaloBios Pharmaceuticals disclosed Monday that the biotech firm has raised $12M in a second close of its Series D venture funding. According to the firm, the additional capital came from Baxter International Inc. The firm closed a $20M Series D in September, which included Genzyme Ventures, Mitsubishi UFJ Capital, MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Ventures, Singapore Bio-Innovations, Pte., and 5AM Ventures. KaloBios is developing antibodies to treat cystic fibrosis, asthma and rheumatoid arthritis, and cancer. More information »